These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 421233)

  • 1. Pharmacology and toxicology of alpha-2'-deoxythioguanosine in cancer patients.
    LePage GA; Khaliq A
    Cancer Treat Rep; 1979 Jan; 63(1):53-7. PubMed ID: 421233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man.
    Lu K; Benvenuto JA; Bodey GP; Gottlieb JA; Rosenblum MG; Loo TL
    Cancer Chemother Pharmacol; 1982; 8(1):119-23. PubMed ID: 7094197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog.
    Loo TL; Lu K; Benvenuto JA; Rosenblum MG
    Cancer Chemother Pharmacol; 1981; 6(2):131-6. PubMed ID: 7307231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects in mice produced by a 3'-branched homologue of alpha-2'-deoxythioguanosine.
    LePage GA; Banks PA; Noujaim MJ; Buzzell GR
    Cancer Chemother Pharmacol; 1980; 5(2):127-31. PubMed ID: 6894108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of beta-2'-deoxythioguanosine in adult acute leukemia.
    Omura GA; Vogler WR; Smalley RV; Maldonado N; Broun GO; Knospe WH; Ahn YS; Faguet GB
    Cancer Treat Rep; 1977 Oct; 61(7):1379-81. PubMed ID: 338147
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.
    Higgins GR; Jamin DC; Shore NA; Momparler R; Hartman G; Siegel SE
    Cancer Treat Rep; 1985 Jun; 69(6):699-701. PubMed ID: 3860294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.
    Momparler RL; Momparler LF; Samson J
    Int J Cancer; 1982 Sep; 30(3):361-64. PubMed ID: 6182115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
    Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
    Gagliano RG; Panettiere FJ; Haas CD; Baker L; Hewlett J; Stuckey WJ; O'Bryan RM; Bottomley R; Heilburn LK
    Cancer Clin Trials; 1981; 4(4):401-5. PubMed ID: 7318121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
    Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
    Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
    Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
    Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
    Griffin JP; Newman RA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
    Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
    Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.